Isotretinoin-Induced Dyslipidemia: a Single-Center Study in Saudi Arabia
Mahdi Al Dhafiri,Feroze Kaliyadan,Sara Almukhaimar,Fatemah Alsultan,Elham Al Hayim,Roaa Alnaim,Alaa Aldossari
DOI: https://doi.org/10.2147/ppa.s445904
2024-01-20
Patient Preference and Adherence
Abstract:Mahdi Al Dhafiri, 1 Feroze Kaliyadan, 2 Sara Almukhaimar, 3 Fatemah Abdulrahman Alsultan, 3 Elham Al Hayim, 3 Roaa Alnaim, 3 Alaa Aldossari 3 1 Department of Dermatology, College of Medicine, King Faisal University, Al-Ahsa, Eastern Province, Saudi Arabia; 2 Department of Dermatology, Sree Narayana Institute of Medical Sciences, Chalaka, Ernakulam, Kerala, India; 3 College of Medicine, King Faisal University, Al-Ahsa, Eastern Province, Saudi Arabia Correspondence: Sara Almukhaimar, College of Medicine, King Faisal University, Al-Ahsa, Eastern Province, 31982, Saudi Arabia, Tel +966560492224, Email Purpose: Acne is a chronic inflammatory skin disease with a high prevalence in Saudi Arabia. Isotretinoin is used to treat severe, resistant nodulocystic acne. Side effects include joint discomfort, headache, mucosal dryness, and nose bleeds. Elevated lipids and liver enzymes have also been recorded. The study goal is to identify the prevalence of increased lipid levels during and after isotretinoin use. Patients and Methods: This retrospective study was conducted in the dermatology polyclinic at King Faisal University, Al-Ahsa, Saudi Arabia. It included adults of different age groups diagnosed with acne vulgaris and treated with oral isotretinoin between January 2021 and December 2022. Parameters included baseline laboratory tests and follow-up laboratory results of cholesterol and triglycerides. Results: Among 88 patients, 48.9% were aged 21– 23 years, with females dominating. In total, 47.7% of patients started using isotretinoin at age 20 years or less, with starting doses ranging from 10 to 20 mg. Fifty percent of the patients had five months or more of treatment duration and only 6.8% of the patients had previously used isotretinoin. For the cholesterol and triglycerides, 87.5% of patients had normal pre-treatment with cholesterol and 90.9% with triglycerides, followed by 81.8% and 95.5% in the second reading, respectively. In the last reading, results were 77.3% for cholesterol and 94.3% for triglycerides. Conclusion: The study found that most acne patients treated with isotretinoin had normal cholesterol and triglyceride levels at baseline, second, and last readings. The incidence of higher laboratory alterations was low, with 12.5% and 4.5% for cholesterol and triglycerides at baseline, and 18.2% and 3.4% at second, and 22.7% and 5.7% at last readings. Overall, age, gender, age of start of isotretinoin, isotretinoin dose, and previous use of isotretinoin are factors that could affect laboratory readings. Keywords: acne, lipids, prevalence, roaccutane, triglycerides, cholesterol Acne is a chronic inflammatory skin disease. The factors that lead to lesion formation include increased sebum production, hyperkeratinization, Cutibacterium acnes colonization, and the subsequent inflammatory reactions are the main therapeutic targets. 1 In Saudi Arabia, the prevalence of acne vulgaris in 2022 was 53%. About 54% of the female and 50% of the male participants both had acne vulgaris. 2 Acne had a significant negative impact on the quality of life for young ladies, with 85.5% prevalence in the eastern region of Saudi Arabia. 3 Substantial mental health burden is associated with treatment-resistant acne during isotretinoin therapy and the potential impact of medication side effects. 4 Isotretinoin is a retinoic acid derivative taken orally for the treatment of moderate to severe, nodulocystic acne that is resistant to conventional medications. It primarily works by decreasing the number of sebaceous glands, the amount of the produced sebum, and the bacterial skin microflora. 5 The possible side effects of isotretinoin including joint discomfort, headache, mucosal dryness, and nose bleeds were the most frequent side effects of isotretinoin treatment, along with lipid profile and liver enzyme changes. 6,7 Interestingly, a study conducted in Al-Ahsa, Saudi Arabia, showed that more than half of participants (58.7%) did not consider lipid profile changes as a risk of using isotretinoin. 8 Following isotretinoin treatment, changes in lipid profile (total cholesterol and triglycerides) and liver enzymes (aspartate transaminase and alanine transaminase) have been recorded. 6,9 A recent study done during 2021 in Qassim University Medical City, Saudi Arabia, showed triglyceride levels and total cholesterol were elevated at the end of treatment course, 12.7% and 9%, respectively. Obesity was the major factor associated with high triglyceride levels, with a significant association between body weight and elevation of triglyceride levels. 10 Our aim -Abstract Truncated-
medicine, general & internal